Eli Lilly and Co
(MIL:1LLY)
€
1,037.4
-22.4 (-2.11%)
Market Cap: 930.72 Bil
Enterprise Value: 964.17 Bil
PE Ratio: 42.22
PB Ratio: 34.04
GF Score: 76/100 Eli Lilly and Co at Citi BioPharma Conference (Virtual) Transcript
Sep 09, 2021 / 01:45PM GMT
Michael Guba;Citigroup Inc.;Healthcare Sector Specialist
Research Division
Hi. My name is Michael Guba. I'm Citi's U.S. Healthcare Sector Specialist, filling in for Andrew Baum, who's our Global Head of Healthcare Research on -- covers major pharmaceuticals here for Citi. I'm lucky enough to be joined by Anat Ashkenazi, Senior Vice President and CFO of Eli Lilly, for a quick little fireside chat here.
Taking verbose tact here, I'm here to moderate, not monopolize. So please feel free to send any of your questions to [email protected]. I'll start off with a couple of openers. But obviously, the whole point of the conference is to have a solid investor participation, so I'd appreciate anything you guys have to ask.
Anat, thank you for joining us today.
Anat Ashkenazi
Eli Lilly and Company - Senior VP & CFO
Great. Great to be here.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot